<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006170</url>
  </required_header>
  <id_info>
    <org_study_id>DTGkids</org_study_id>
    <nct_id>NCT05006170</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV</brief_title>
  <official_title>Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate steady-state pharmacokinetics of DTG dispersible&#xD;
      tablets in children with HIV infection weighing from 6 to below 20 kg and to determine the&#xD;
      dose of DTG that achieves adult target PK parameter(trough concentration; AUC24h)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all legal guardians giving written&#xD;
      informed consent will undergo check eligibility to enroll the study entry. Patients will be&#xD;
      sort into 3 weight band groups 6 to below 10 kg, 10 to below 14 kg, and 14 to below 20 kg.&#xD;
      ARTs will be switched to DTG dispersible tablet and ABC/3TC once daily will be prescribed&#xD;
      according to weight band dosage. Total of 7 time point of blood sampling for plasma DTG&#xD;
      concentrations will be measure at 7-14 day after medication switch. Patient will be follow up&#xD;
      as schedule for total 24 week to assess safety, and efficacy of DTG dispersible tablet&#xD;
      combine with ABC/3TC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Steady-state pharmacokinetics of DTG dispersible tablets in children with HIV infection</measure>
    <time_frame>At 7-14 day after started on DTG</time_frame>
    <description>Trough plasma DTG concentration and DTG exposure (AUC24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse event incidence</measure>
    <time_frame>24 week after medication switched</time_frame>
    <description>Incidence of grade 3 and 4 adverse events in use of DTG for HIV treatment in</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiretroviral activity of dolutegravir dispersible tablets combined with two standard background therapies</measure>
    <time_frame>24 week after medication switched</time_frame>
    <description>HIV VL &lt;40 copies/mL</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pediatric HIV Infection</condition>
  <arm_group>
    <arm_group_label>6 to below 10 kg weight band</arm_group_label>
    <description>Children with perinatal HIV infection whose weight from 6 kg to below 10 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 to below 14 kg weight band</arm_group_label>
    <description>Children with perinatal HIV infection whose weight from 10 kg to below 14 kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14 to below 20 kg weight band</arm_group_label>
    <description>Children with perinatal HIV infection whose weight from 14 kg to below 20 kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG DT 20 mg</intervention_name>
    <description>Give 2 tabs of MYLTEGA DT (10mg) PO once daily</description>
    <arm_group_label>10 to below 14 kg weight band</arm_group_label>
    <arm_group_label>6 to below 10 kg weight band</arm_group_label>
    <other_name>MYLTEGA Dispersible Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTG DT 25 mg</intervention_name>
    <description>Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily</description>
    <arm_group_label>14 to below 20 kg weight band</arm_group_label>
    <other_name>MYLTEGA DT Dispersible Tablet</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children with perinatal HIV infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children living with HIV weighing 6 to below 20 kg&#xD;
&#xD;
          -  Na√Øve to integrase inhibitors&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Currently active opportunistic infection&#xD;
&#xD;
          -  Liver dysfunction (SGPT below 100 IU/mL)&#xD;
&#xD;
          -  Renal dysfunction (GFR below 60 mL/min)&#xD;
&#xD;
          -  Currently using medication that interacts with DTG&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athiporn Premgamone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thanyawee Puthanakit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athiporn Premgamone, MD</last_name>
    <phone>+6622564000</phone>
    <phone_ext>4930</phone_ext>
    <email>athiporn.p@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thanyawee Puthanakit, MD</last_name>
    <phone>+6622564000</phone>
    <phone_ext>4930</phone_ext>
    <email>thanyawee.p@chula.ac.th</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dolutegravir dispersible tablet</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>weight below 20 kg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

